Ultivue combines expertise in the development of high-quality multiplex immunofluorescence assays and AI-based computational pathology. It allows us to see many more cell phenotypes by adding highly specific staining channels, and with the help of AI, their spatial relationships, or spatial biology. Immunofluorescence is the color photography equivalent of pathology. only looking at H&E stained sections) can be compared to using black-and-white photography to spot yellow tulips in a red tulip field. Trying to understand the tumor-immuno microenvironment through the eyes of ‘Digital Pathology’ (i.e. Neither pathologists nor AI can reveal the required information from H&E sections since it was not captured when the tissue section was stained and digitized.
To complicate things, most of these cell types can be subdivided into a vast number of “specializations” and states of activities that cannot be distinguished from H&E slides anymore. With the advent of immune therapy, a more granular characterization of the immune system (and tumor cells) has become necessary to support clinical pathology and diagnostics.Īt a high level, our immune system comprises multiple different cell types (T cell, B cell, etc.), which are difficult to distinguish in H&E slides. Ultivue is one such healthcare technology (HealthTech) company that provides high-quality multiplex immunofluorescence assays and large-scale, AI-based computational pathology-built on Amazon Web Services (AWS). AI companies have formed on the idea that AI can complement the expert assessment of H&E slides by a pathologist. AI tools can complement expert assessment with quantitative measurements to enable data-driven medicine. They accumulated a comprehensive body of knowledge on how combined insights from tissue and cell morphologies characterize disease and guide treatment selection. Pathologists have been looking at morphological patterns in patients’ tissue sections highlighted by Hematoxylin and Eosin (H&E) staining for more than a century. Together they unlock the pathway to precision medicine and will be among our strongest weapons to fight cancer. While microscopes still dominate many workflows, digital pathology combined with artificial intelligence (AI) is disrupting the space. Pathology is currently undergoing a transformation. This is a guest post by Moritz Widmaier, product manager Martin Shulze, principal consultant for technology and IT and Florian Leiss, vice president (VP) of product strategy and corporate development, at Ultivue. Pictured: Tissue sample stained with H&E and immunofluorescence (IF) markers side by side.
0 kommentar(er)
